Spi-B and PU.1 are hematopoietic-specific transcription factors that constitute a subfamily of the Ets family of DNA-binding proteins. Here we show that contrary to previous reports, PU.1 and Spi-B have very different expression patterns. PU.1 is expressed at high levels in B cells, mast cells, megakaryocytes, macrophages, neutrophils, and immature erythroid cells and at lower levels in mature erythrocytes. PU.1 is completely absent from peripheral T cells and most T cell lines based on sensitive R.T-PCR assays. In contrast, Spi-B is expressed exclusively in lymphoid cells and can be detected in early fetal thymus and spleen. In situ hybridizations of adult murine tissues demonstrate Spi-B mRNA in the medulla of the thymus, the white pulp of the spleen, and the germinal centers of lymph nodes. Spi-B expression is very abundant in B cells and both Spi-B mR.NA and protein are detected in some T cells. In situ hybridization and Northern blot analysis suggest that Spi-B gene expression increases during B cell maturation and decreases during T cell maturation. Gel-retardation experiments show that Spi-B can bind to all putative PU.1 binding sites, but do not reveal any preferred Spi-B binding site. Finally, both PU.1 and Spi-B function as transcriptional activators of the immunoglobulin light-chain enhancer E~2.4 when coexpressed with Pip (PU.l-interaction partner) in NIH-3T3 cells. Taken together, these data suggest that differences in patterns of expression between Spi-B and PU. 1 distinguish the function of each protein during development of the immune system.
H
ematopoiesis generates eight distinct lineages from self-renewing pluripotential stern cells, which then differentiate into mature blood cells. The molecular mechanisms underlying self-renewal and lineage commitment of stem cells have not been resolved. However, the process is regulated in part by hematopoietic-specific transcription factors. For example, stem cell leukemia (SCL) 1 is required for yolk sac hematopoiesis (1, 2), GATA-1 regulates red cell maturation (3, 4) ; Ikaros is important for the development of lymphocytes, natural killer cells, and neutrophils (5, 6) ; and Oct-2 is essential for T cell-independent B cell activation and B cell maturation into immunoglobulin secreting cells (7, 8) . The function of a transcription factor in hematopoiesis is somewhat correlated to its expression pattern. PU.1 is expressed at high levels in B cells, granulocytes, monocytes, and immature erythroid cells (9, 10, 11, 12) . We have previously determined that PU.1-/--defi1Abbreviations used in this paper: CAT, chloramphenical acetyl transferase; DN, double negative; DP, double positive; EMSA, electrophoretic mobihty shift assays; Fc~/R, Fc fragments; IVT, in vitro-translated; RT, reverse transcribed; SCL, stem cell leukemia; SP, single positive. cient embryos die between days 16 and 18 of gestation and mutant embryos do not produce T and B lymphocytes, granulocytes, and monocytes (13) . In addition, some day 16.5 embryos are also anemic (13) .
Transcription factors of the Ets family are widely studied as key regulators of genes involved in the immune response and cellular prohferation. Spi-B and PU.1 are members of the Ets family, which now includes ~20 members. Spi-B was cloned from a Burkitt lymphoma cDNA hbrary using the human PU.1 Ets DNA-binding domain as a probe (12) , and it shares a 67% amino acid Ets-domain identity and 43% overall amino acid sequence identity to PU.1 (12) . Like most of the Ets family members, Spi-B has the DNAbinding domain at its basic carboxy terminus and an acidic amino-terminal domain that corresponds to the transactivational domain in PU.1. PU.1 and Spi-B are the most distantly related genes to other Ets family members, as their Ets domains present only 40% identity to Ets-1 (12) . Spi-B can bind specifically to the putative PU.1 binding site in the SV40 promoter, and can also transactivate a reporter construct containing multiple PU boxes. Ray et al. reported that Spi-B has an identical pattern of expression to PU.1 and is expressed in all hematopoietic hneages except T cells (12) .
Here we report that significant amounts of Spi-B mRNA are detected in B and T cells, but not in monocytic cells. On the contrary, PU. 1 mP,.NA can not be detected by the most sensitive means, such as tLT-PCP,, in purified human peripheral T cells or any T cell lines examined. Spi-B is not present in any other non-lymphoid cells based on in situ hybridization analyses. Spi-B is first expressed in the fetal thymus and spleen, and Spi-B mP, NA is localized to the medulla of the thymus, white pulp of the spleen, and the germinal centers of the lymph nodes of adult mice. Spi-B is able to bind to all predicted PU. 1-binding sites in vitro, including myeloid target genes. Both Spi-B and PU.1 in Clone 13 B cells bind to the functional PU.l-binding site in the IgK 3' enhancer. Both Pu.1 and Spi-B function as transcriptional activators of the Igk 2-4 enhancer. We postulate that Spi-B plays an important role in lymphocytic development based on its pattern of expression.
Materials and Methods
Northern Analysis and RT-PCR. Total ILNAs were prepared from cells or tissues using Trizol (GIBCO BILL, Gaithersburg, MD) according to the manufacturer's instructions. Poly-A + R.NAs were then prepared from total cellular ILNAs using the Oligotex poly-A § miLNA purification protocol (QIAGEN, Chatsworth, CA). Poly-A + ILNA samples (2 ~g each) were separated by electrophoresis on 1.2% agarose gels containing formaldehyde and blotted onto Hybond-N+ membranes. Hybridizations were carfled out at 42~ in 50% formamide, 50 mM hepes (pH 7.0), 5• Denhardt's solution, 3• SSC, 0.16 mg/ml salmon sperm DNA, 0.1% SDS, and 5% dextran sulfate. Membranes were washed twice in 2X SSC/0.1% SDS at room temperature for 10 rain, and twice in 0.1• SSC/0.1% SDS at 55~ for 30 rain. The human Spi-B probe (3'-UTIL, from the EcoiLV site in Spi-B to the EcoiLI site in pBluescript, ,'~ bp long) and murine Spi-B probe (3'-UTIL, NdeI to BamHI, 600 bp long) were labeled by random hexapriming.
For ILT-PCIL analysis, total ILNA was reverse transcribed (ILT) in a 20-p2 volume with reagents from Perkin-Elmer (Norwalk, CT): Moloney murine Leukemia virus reverse transcriptase (50 U), R.Nase inhibitor (20 U), dNTPs (1 mM final concentration), Oligo d(t)l 6 (2.5 mM final concentration), MgC12 (5 mM final concentration), KC1 (50 mM final concentration), and Tris-HC1, pH 8.3 (10 mM final concentration). Samples were incubated at 42~ for 15 min 99~ for 5 min, and 5~ for 5 rain. The salt concentration for PCIL was optimized using the Optiprime kit (Stratagene, La Jolla, CA) for each set of primers according to the manufacturer's instruction. The entire ILT reaction was subjected to 30 cycles of denaturation at 94~ for 1 rain, primer annealing at 65~ and primer extension at 72~ for 2 rain.
Antibodies. The coding sequence of human Spi-B cDNA was subcloned into the EcoR.I site of the bacterial expression vector pGEX-4T3 (Pharmacia, Piscataway, NJ). Spi-B-GST fusion protein was induced at 1.25 mM IPTG and subsequently purified using the Bulk GST Purification Module (Pharmacia). Polyclonal anti-Spi-B antisera were obtained from rabbits immunized with the Spi-B-GST fusion protein (Pocono Rabbit Farm & Laboratory, Canadensis, PA). Monodonal anti-PU. 1 antibody was purchased from Santa Cruz Biotechnology, Inc.
In Vitro Translation and Western Blot Analysis. IVT proteins were synthesized from human Spi-B and murine PU.1 cDNA linked to the T7 promoter in pCDNA3 vectors using Promega TNT T7 Coupled ILeticulocyte Lysate System. IVT proteins were quantitated by their [3SS]methionine incorporation, to determine that equal amounts of Spi-B and PU. 1 proteins were loaded for each assay. IVT proteins and total cell lysates obtained from 2 • 10 6 cells each were subjected to 12% SDS-polyacrylamide gel electrophoresis followed by electrotransfer onto nitrocellulose. The membranes were probed with the polyclonal antiserum to Spi-B in 10 mM Tris, pH 7.5, 150 mM NaCI, and 5% nonfat milk. The immune complexes were revealed by the ECL Western blotting detection system (Amersham Corp., Arlington Heights, IL) according to the manufacturer's instructions.
Ceil Purification. To purify splenic B cells, ammonium chloridelysed spleen cells were subjected to anti-Thyl.2/complement depletion. Splenic T cells were purified from red cell-depleted spleens using a Mouse T Cell Enrichment Column (IL&D Systems, Minneapolis, MN) and anti-JllD/complement lysis. The purity of final cell populations was determined by flow cytometry using B220 (13 cell) and CD3 (T cell) surface antigens. Purified B cells were determined to be 98% pure, and T cells were 85% pure. For T cell sorting, adult BL/6 thymi were processed into single cell suspensions and resuspended at 5 3< 106 cells per ml in 5% complete media (5% fetal bovine serum, 1• non-essential amino acids, 1• L-glutamine, 1 • Pen-Strep, 50 I.tM [3-mercaptoethanol in DMEM). Thymocytes were incubated with anti-CD4 and anti-CD8 antibodies (PharMingen, San Diego, CA) at 1 p~g/106 cells for 30 min at 4~ The incubation was followed by two washes with complete media. Cells were resuspended at 4 • 106 cells/ml in complete media for sorting by flow cytometry.
In Situ Hybridization. Adult murine tissues (thymus, lymph nodes, heart, lung, spleen, and liver) were sectioned and mounted for in situ hybridization. Sense and anti-sense riboprobes were made from the 3'-UTIL of murine Spi-B (NdeI to BamHI) linked to the T7 promoter in pBluescript. The protocol utilized was essentially as described by Eichele and coworkers (14) . Tissues were fixed in 4% paraformaldehyde/PBS and embedded in paraffin. The sections were rehydrated and treated with 20 mg/ ml proteinase K, and 0.1 M triethanolamide-HCl, pH 8. Pretreated slides were hybridized overnight at 60~ The hybridization mix contained 50% formamide, 20 mM Tris-HCl, pH 8, 0.3 mM NaCl, 5 mM EDTA, 10% dextran sulfate, 0.02% BSA, 0.5 mg/ml tiLNA, and 10 mM DTT. 3SS-labeled riboprobe was mixed with the hybridization mix at 140,000 cpm/1 (90 ml/ slide). A 1/100th volume of 25 mM 5'-alpha-thio-ATP was added to the probe mix, followed by 2 min of boiling. After hybridization, slides were washed with 50% formamide, 2• SSC, and 20 mM DTT for 60 min at 65~ (high stringency wash). Slide were then washed with STE (4• SSC, 20 mM Tris-HC1, pH 7.6, 1 mM EDTA) for 10 min twice at 37~ followed by ILNase A treatment (10 mg/ml in STE) for 30 min at 37~ This high stringency wash was repeated and then the slides were washed in 2• SSC at 37~ for 10 min.
Electrophoretic Mobility Shift Assays (EMSAs). In vitro-translated (IVT) proteins (1.3 ~1 to 1.5 I*1) or nuclear extracts (10 Ixg) were preincubated on ice with 1 Ixg of double-stranded poly(dI-dC) and 0.4 Izg of salmon sperm DNA in 5X Ficoll binding buffer in a final volume of 19 p~l. For competition experiments, cold competitor oligonucleotide (200-300 ng per reaction) and pre-immune or antiserum were also added at this step. ILadiolabeled probes were diluted to 30,000 cpm/p.1 and 1 ~1 was added to the binding reaction for a 10-rain incubation at room temperature. Oli-gonucleotides were synthesized according to the pubhshed putative PU. (20) . To create Pip/CMV the Pip cDNA was subcloned as a HindllI-XbaI fragment into the HindlII and Xbal sites in the polylinker of pRc/CMV (Invitrogen), which places the cDNA insert under the control of the CMV promoter (21) . NIH-3T3 cells were transfected using Lipofectin (GIBCO BRL) and a total of 25 btg of DNA. Transfection involved 5 ~g of reporter construct and 10 Ixg of the expression constructs, with the balance made up with empty expression vector. After 48 h at 37~ cell lysates were prepared and CAT assays performed using 30 txl oflysate as described previously (20) . TLC plates were analyzed on a Molecular Dynamics Phosphorlmager; the results shown here represent an average of at least four independent transfections. (12) , so splenocytes were used as a positive control. As shown in Fig. 1 A, high levels of Spi-B m R N A were detected in adult splenocytes (see lane 1). The predominant m R N A species was 3.0 kb, in contrast to the 1.4-kb species found in human cells (see Fig. 6 ). However, a faint 1.5-kb species was detected. Surprisingly, Spi-B m R N A was detected at low levels in adult thymocytes as well ( Fig. 1 A, lane 2). In contrast, Spi-B m R N A s were completely absent in all fetal tissues examined including heart, kidney, brain, and liver ( Fig. 1 A, lanes 3-6) . Adult murine tissues were also examined for Spi-B expression, including heart, liver, lungs, lymph nodes, small intestine, spleen, and testes. Be- . A 3.0-kb transcript was detected in the spleen and lymph nodes; however, no 1.5-kb species was apparent in this experiment. GAPDH hybridization is shown in the bottom panel A larger GAPDH transcript was observed in the testes sample.
Results

Spi-B mRNAs Are Present Exclusively in Murine Thymus
sides the spleen, Spi-B m R N A s were also detected in axillary and mesenteric lymph nodes ( Fig. 1 B, lanes 4 and 6) . N o other organs from adult mice exhibited significant Spi-B expression.
To further localize Spi-B m R N A expression, in situ hybridization was performed on adult mouse tissues. In adult tissues, Spi-B m R N A was observed exclusively in the thymus, spleen, and lymph nodes (Figs. 2 and 3) . Only background signals were detected in heart, intestines, kidney, stomach, lung, and liver (data not shown). To assess positive in situ hybridization, sense and antisense 3' U T R Spi-B probes were incubated with tissue sections. As shown in Fig. 2, a, d , and g, the sense probe gave weak hybridization signals as compared to the antisense probe (b, e, and h). Hematoxylin-and eosin-stained sections of thymus, spleen, and lymph nodes are shown for comparison (Fig. 2, c , f, and 0.
In the thymus, Spi-B gene expression was restricted to the medulla region (Fig. 2, b) . As T cells mature, thymocytes
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Suet al. Figure 2 . The spatial pattern of expression of Spi-B in the thymus, spleen and lymph nodes. In situ hybridization analyses were perfonned using a radiolabeled sense 3' UTR Spi-B riboprobe (a, d, and g) and an antisense Spi-B riboprobe (b, e, and h). Specific hybridization was detected m the thymus medulla (b), white pulp of the spleen (e), and follicles and germinal centers of the lymph nodes (h). c.jl and i display hematoxylin-and eosin-stamed see tions of adjacent regions of the thymus, spleen, and lymph node for comparison. Magnification, 5• migrate from the darkly staining thymic cortex to the pale staining medulla where single positive T cells undergo negative selection. In the spleen, Spi-B mP,,NA was abundantly expressed throughout the white pulp, except the center portion which consists of arterioles and periarteriolar lymphocyte sheaths (PALS) (Fig. 2, e) . The PALS contains a network of antigen-presenting cells, such as interdigitating dendritic cells, and plasma B cells. B cells congregate peripherally to the PALS in primary follicles and germinal centers. The outer most layer of the white pulp is the marginal zone, which contains T and B lymphocytes. Spi-B mP, NA is present in cells surrounding the arterioles and the PALS in the white pulp of the spleen, where T and B lymphocytes reside. In lymph nodes, Spi-B is present in the primary follicles (Fig. 2, h and 0 . Fig. 3 , shows in situ hybridization analyses with the thymus (b), spleen (e), and lymph nodes (h) at a higher magnification. Spi-B mtLNA was present in the periphery of the thymic medulla and the germinal centers of the spleen (b and e). Fig. 3 i, shows a resting lymph node stained with hematoxylin and eosin; the primary follicles reside at the edge. Resting B cells accumulate in the follicles which clearly express Spi-B (Fig. 3 h) . Fig. 4 and show that Spi-B lnRNAs were detected exclusively in fetal thymus and spleen. Spi-B expression was first observed in the day 14.5 thymus (Fig. 4 , ,/and c). All tissues in day 7.5, 8.5, and 10.5 embry, os failed to react with the antisense Spi-B probe and gave background signals similar to that observed with the control sense probe shown in Fig. 4 b. Furthermore, all other tissues in the day 14.5 embryo were negative for Spi-B mR.NA production (see Fig. 4 a) . It is interesting to note that neither the day i4.5 or day 16.5 spleen exhibited Spi-B gene expression. However, when sections of day 19.5 embryos were hybridized to the Spi-B probe, the spleen displayed strong signal intensity (Fig. 4 e) . The control sense probe gave the expected background level of hybridization (Fig. 4 d) . In
Spi-B Expression Is
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Ets Protein Spi-B Is Expressed Exclusively in B Cells and T Cells the day 19.5 embryo, Spi-B hybridization was detected only in the thymus and spleen. We conclude that Spi-B gene expression is highly tissue restricted and can only be detected in the developing lymphoid organs of the mouse embryo. (Fig. 5 C) . Furthermore, Rag2 -/-thymi express higher levels than those obtained from C57BL/6 mice (lanes 5 and 6). Rag 2 -/-thymi have previously been shown to contain no DP or SP T ceils and to contain essentially 98% D N cells (22) . These results are consistent with Spi-B expression being highest in D N T cell precursors. Furthermore, Spi-B expression was higher in the immature T cell line, EL-4, than the mature T cell line, IkMA (Fig. 5 A, lanes 7 and 8) . Therefore, Spi-B gene expression increases during B cell maturation and decreases during T cell maturation. Surprisingly, some PU.1 expression was also detected in the C D 4 -C D 8 -sorted T cells (Fig. 5 C) , although it was completely absent in a number o f human T cell lines examined by R T -P C R analyses (Jurkat, H9, Molt 3) and purified human peripheral T cells (data not shown). R T -P C R . assays for M-CSF receptor expression indicated that the R N A samples contained no contaminating monocytic cells (data not shown). Finally, it should be noted that Spi-B was found in EL-4 T cells, thymocytes, and the thymus when these samples were run separately (Fig. 5 B) .
Spi-B Expression Is Developmentally Regulated during T Cell and B Cell
Spi-B Is Highly Expressed in Human B Cells and Some T Cells at Both the RNA and Protein Levels. Several human cell
lines were examined for Spi-B expression by poly-A + R N A Northern blot analysis as shown in Fig. 6 . Spi-B R N A w'~is detected in clone 13 B cells (lane /), but was not present in monocytic cells such as U937 and K562 andJurkat T cells (lanes 3-5) . Furthermore, TPA treatment ofU937 cells (which converts them from monoblasts to monocytes) did not induce Spi-B (lane 2). Spi-B expression was not apparent in the non-hematopoietic epithelial ceil line HeLa or Hep G2 hepatic cells (lanes 6 and 7) .
To determine the tissue specificity of Spi-B protein expression and to confirm that the level of gene expression correlated with the level of protein expression, Western blot analyses were performed. Polyclonal antiserum raised
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Ets Protein Spi-B Is Expressed against human Spi-B-GST fusion protein was specific for in vitro-translated (IVT) human Spi-B in immunoblotting assays (Fig. 7) . Importantly, pre-immune sera failed to bind IVT Spi-B, PU.1, and JunB (Fig. 7 A, lanes 1-3) , while polyclonal antisera for Spi-B-GST specifically recognized IVT Spi-B (lane 4). Furthermore, it did not cross-react with IVT PU.1, c-Fos, or JunB (lanes 5-7) . Surprisingly, Exclusively in B Cells and T Cells (Fig. 7, A and B) . N o Spi-B protein was detected in the monocytic cell lines K562 and U937 (Fig. 7 A, lanes 9 and 11) or HeLa epithelial cells (lane 12).
The level o f protein expression correlated with the abundance ofSpi-B mRNAs. It is not surprising that Clone 13 and H9 express Spi-B proteins, since they both contain high levels o f Spi-B rnRNAs (Fig. 6 and data not shown) . It is interesting to note that H9 T cells are less mature than either Jurkat or Molt3 cells (23) . Furthermore, IM-9 cells are less mature than R.aft, CCRF-SB, RPM1 7666, R.PM1 1788 cells, and WIL2-NSB cells. Therefore, Spi-B expression appears to decrease as human T cells mature and increase as human B cells mature, as was noted in murine lymphocytes. Finally, no Spi-B protein was detected in peripheral human T cells (data not shown). proteins other than PU. 1 and Spi-B in the T N T reticulocyte lysate bound to the labeled oligonucleotides (data not shown). The binding of both IVT PU.1 and Spi-B (which yielded a slower mobility EMSA complex) was shown to be specific in a series of competition assays (Fig. 8 A) . The wild-type cold competitor oligonucleotides competed with PU.1 and Spi-B binding activities (lanes 2, 5, 8, and 11), but not competitor oligonucleotides harboring mutations in the core 5 ' -G G A A -3 ' sequence o f each PU.1 binding site (lanes 3, 6, 9, and 12). The binding activity of PU.1
Spi-B Specifically Binds to Putative PU. 1 Binding Sites in
and Spi-B was compared for oligonucleotides derived from the c-fes promoter and the SV40 enhancer. The binding activity of Spi-B to the PU. 1-binding site in SV40 was similar to that of PU.1, however Spi-B appeared to bind more weakly to the c-fes promoter (see Fig. 8 A, lanes 1, 4, 7 , and 10). Spi-B bound specifically and with similar affinity to PU.1 to the sites in the M -C S F R and FC2tRI promoters (Fig. 8 B, lanes 1-8) . However, Spi-B bound to the P U sites in J chain promoter and the 3' enhancer o f IgK with lower affinity than PU.1 (lanes [13] [14] [15] [16] [17] [18] [19] [20] . Interestingly, both PU.1 and Spi-B bind strongly to the ~-globin intervening sequence 2, (lanes 9-12). Table 1 To determine if Spi-B in B cell nuclear extracts can also bind to a P U . l -b i n d i n g site in the IgK 3' enhancer, a series of binding experiments were performed on extracts obtained from clone 13 human B cells. First, antibodies specific for both PU.1 and Spi-B were tested for cross reactivity on purified proteins. As shown in Fig. 9 A, the anti-PU.1 antibody inhibited PU. 1 binding to a c-fes promoter oligonucleotide and did not interfere with the binding of IVT Spi-B (lanes 3 and 4) . Furthermore, the anti-Spi-B anti- 5 and 6) . As expected, pre-immune sera did not affect the binding of either protein (lanes 7 and 8) .
Having demonstrated that these antibodies are specific for either PU.1 or Spi-B, binding assays were performed on human B cell nuclear extracts. As shown in Fig. 9 B, two specific complexes were detected using the IgK 3' oligonucleotide (bands 2 and 3 in lane 1). Both of these complexes were competed by 200 ng of cold IgK 3' oligonucleotide while band 1 was not (lane 2). Pre-immune sera did not affect either the specific or non-specific DNA-protein complexes (lane 3). However, the antibody specific for Spi-B allowed the detection of a DNA-protein complex with a rapid mobility and the antibody specific for PU.1 allowed the detection of a complex with a slower mobility (lanes 4 and 5). We conclude that the addition of anti-Spi-B antibody allowed the detection of the rapidly migrating PU.1-DNA complex and the more slowly migrating Spi-B-DNA complex was revealed by the addition of the anti-PU.1 antibody. When both Spi-B and PU.1 antibodies were added to these reactions, both PU. 1-and Spi-B-binding were eliminated (lane 6). The migration of PU.1 and Spi-B was confirmed by their co-migration with IVT PU. 1 and Spi-B (lanes 7 and 8). We conclude that both PU.1 and Spi-B in clone 13 B cell nuclei are capable of binding the PU.l-binding site in the IgK 3' enhancer in an in vitro assay.
Spi-B Functions as a Transcriptional Activator of a B Cell-specific Gene. PU.1 and Pip (PU.1 interaction partner) form a B cell-specific heterodimeric protein complex that regulates the expression of the Igk enhancer Eh2_ 4 (21) . PU.1 and Pip bind to a composite element in this enhancer that is essential for enhancer activity (20) . Furthermore, PU.1 and Pip function as mutually dependent transcriptional activators of this element when coexpressed in NIH-3T3 cells (21) . Having shown that Spi-B can bind to multiple PU.l-binding sites in B cell--specific genes, we wanted to learn if Spi-B can also function as a transactivator of the lambda Ex2_ 4 element. The kB element ofEx2_ 4 when multimerized and placed upstream of the thymidine kinase promoter, is transactivated by PU.1 and Pip when coexpressed in NIH-3T3 cells (21) . As shown in Fig. 10, nei 
Discussion
The Ets family of DNA-binding proteins have become the subject of extensive investigation as key regulators of immune response genes and cell division (24) . The Ets family now includes -20 members and their cellular functions and target genes are currently being analyzed. Spi-B and PU.1 share a 67% amino acid Ets-domain identity and 43% overall amino acid identity (12) . It is essential to learn if Spi-B and PU. 1 have similar patterns of expression to begin to understand their respective functions in development and immune cell function.
In contrast to previous reports that Spi-B and PU.1 are coexpressed in a variety ofhematopoietic cells (12, 25) , our data clearly showed that Spi-B expression is restricted to T and B lymphocytes. We detected no human Spi-B R.NA or protein by poly-A + Northern and Western blot analysis in monocytic or erythroid cells. We attribute the divergent results to the different probes used. The 3'-UTIL of Spi-B was used in all of our Northern blot assays as opposed to the full-length cDNA used in the study by Ray et al. (12) . Because the nucleotide sequence similarity between Spi-B and PU. 1 human cDNAs in the DNA-binding domain is 75% (12), we conclude that the myeloid cell expression observed in the previous report represents cross reaction with PU.1. Contrary to previous reports (12), we also detected Spi-B expression in some human T cell lines at the level of both RNA and protein. The polyclonal antiserum raised against a human Spi-B-GST fusion protein was able to Western blot, immunoprecipitate, and ablate DNA binding activity of human Spi-B specifically without any cross-reactivity with PU.1. In Western blot analysis, Spi-B protein was detected in all B cell lines and one T cell line, but not m e n t . T h e s e findings w e r e consistent w i t h h u m a n T cells and m u r i n e a n d h u m a n T cell lines. T h e medullary staining observed for Spi-B in the murine thymus would appear to be inconsistent with high levels of Spi-B RNA in CD4-CD8-T cells. However, it is not clear that the positive selection of developing thymocytes is restricted to the thymic cortex (26) . It remains a formal possibility that CD4-CDS-T cells reside in the medulla. Alternatively, the medullary staining observed may represent expression in antigen presenting cells (B cells and dendritic cells).
Other than the thymus, spleen, and lymph nodes, Spi-B was virtually undetectable in any other organ of either embryonic or adult mice by both poly-A + Northern blot analysis and in situ hybridization. The expression of Spi-B is clearly distinct from that of PU. 1. In situ hybridizations of fetal and adult mouse tissues with the 5' untranslated region of PU. 1 mRNA previously detected PU.1 expression in bone marrow, liver, and spleen of adults and the fetal liver of day 18.5 embryos (11) . Further analysis showed that this was due to high levels of PU.1 in macrophages, neutrophils, mast cells, B cells, and immature erythroid cells (9, 11, 12) . In contrast, Spi-B expression in murine tissues is limited to the lymphoid organs (thymus, spleen, and lymph nodes) and is not detected in the bone marrow or liver. The lack of Spi-B expression in the fetal liver suggests that Spi-B is not present in immature proerythroblasts that are very abundant in the liver during days 12.5 to 16.5 of gestation. Therefore, macrophages, neutrophils, and red blood cells which express high levels of PU.1 completely lack Spi-B. Furthermore, Spi-B was detected in T cells where no PU.1 expression was observed. Therefore, only B cells and CD4-CD8-T cells express high levels of both PU. 1 and Spi-B.
When the binding affinities of IVT PU.1 and Spi-B were compared, Spi-B was able to bind to all published PU.l-binding sites albeit with less affinity in some cases. Since both PU. 1 and Spi-B are present in B cells, it is interesting that both were capable of binding to the 3' enhancer of IgK. Although, Spi-B bound efficiently to the PU.1 binding sites ofM-CSFR, FcyR1, and the scavenger receptor promoters (27) , it is unlikely to regulate these genes as it is not present in monocytes or macrophages. It is intriguing that Spi-B can also transactivate a reporter construct containing the PU. 1 binding site in the lambda chain Ex2_ 4 enhancer. It will be of interest to learn what Spi-B target genes exist in B cells and early T cells. We have previously shown that PU. 1 and Spi-B play nonredundant roles in B cells and T cells: gene targeting ofPU. 1 leads to mice lacking B cells, T cells, monocytes, and neutrophils (13) . It will be of interest to learn how lymphocytic development and function are affected in Spi-B-deficient mice.
